SIB 1893

Drug Profile

SIB 1893

Alternative Names: 2-Methyl-6-(phenylethenyl) pyridine

Latest Information Update: 06 Apr 2010

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neuroprotection

Most Recent Events

  • 06 Apr 2010 No development reported - Preclinical for Neuroprotection in USA (unspecified route)
  • 20 Aug 2002 This compound is still in active development
  • 11 Dec 2000 Preclinical development for Neuroprotection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top